Natixis Advisors’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.7M Buy
102,188
+3,315
+3% +$651K 0.02% 524
2026
Q1
$19.4M Buy
98,873
+1,871
+2% +$364K 0.03% 502
2025
Q4
$16.8M Sell
97,002
-30,362
-24% -$5.53M 0.02% 534
2025
Q3
$24.3M Sell
127,364
-1,718
-1% -$305K 0.04% 425
2025
Q2
$23.2M Buy
129,082
+16,850
+15% +$2.93M 0.04% 423
2025
Q1
$19M Buy
112,232
+8,257
+8% +$1.36M 0.04% 459
2024
Q4
$15.7M Buy
103,975
+11,145
+12% +$1.73M 0.03% 522
2024
Q3
$14.4M Buy
92,830
+6,619
+8% +$989K 0.03% 539
2024
Q2
$11.8M Buy
86,211
+8,863
+11% +$1.21M 0.03% 555
2024
Q1
$10.3M Sell
77,348
-3,253
-4% -$422K 0.02% 600
2023
Q4
$11.1M Buy
80,601
+25,847
+47% +$3.4M 0.03% 531
2023
Q3
$6.67M Sell
54,754
-16,873
-24% -$2.25M 0.02% 620
2023
Q2
$10.1M Buy
71,627
+8,524
+14% +$1.18M 0.03% 526
2023
Q1
$8.93M Buy
63,103
+11,410
+22% +$1.63M 0.03% 529
2022
Q4
$8.09M Buy
51,693
+625
+1% +$89.8K 0.03% 539
2022
Q3
$6.27M Buy
51,068
+3,618
+8% +$476K 0.03% 569
2022
Q2
$6.31M Sell
47,450
-2,990
-6% -$407K 0.03% 584
2022
Q1
$6.9M Sell
50,440
-394
-0.8% -$54.9K 0.03% 583
2021
Q4
$8.79M Buy
50,834
+9,623
+23% +$1.46M 0.03% 501
2021
Q3
$5.99M Sell
41,211
-2,123
-5% -$311K 0.02% 587
2021
Q2
$5.72M Buy
43,334
+8,456
+24% +$1.11M 0.03% 593
2021
Q1
$4.48M Buy
34,878
+2,068
+6% +$255K 0.02% 628
2020
Q4
$3.91M Sell
32,810
-24,072
-42% -$2.93M 0.02% 647
2020
Q3
$6.51M Buy
56,882
+4,152
+8% +$491K 0.04% 438
2020
Q2
$6.01M Sell
52,730
-17,846
-25% -$1.89M 0.04% 448
2020
Q1
$5.67M Buy
70,576
+8,031
+13% +$831K 0.05% 416
2019
Q4
$6.68M Buy
62,545
+1,234
+2% +$129K 0.05% 430
2019
Q3
$6.56M Buy
61,311
+3,663
+6% +$376K 0.05% 395
2019
Q2
$5.87M Buy
57,648
+32,536
+130% +$3.13M 0.05% 409
2019
Q1
$2.26M Buy
25,112
+11,594
+86% +$1M 0.02% 718
2018
Q4
$1.13M Sell
13,518
-22,342
-62% -$2.09M 0.01% 874
2018
Q3
$3.87M Sell
35,860
-300
-0.8% -$32.9K 0.03% 565
2018
Q2
$3.98M Sell
36,160
-1,600
-4% -$167K 0.04% 543
2018
Q1
$3.79M Sell
37,760
-4,252
-10% -$435K 0.04% 535
2017
Q4
$4.14M Buy
42,012
+1,642
+4% +$156K 0.04% 482
2017
Q3
$3.78M Sell
40,370
-6,581
-14% -$699K 0.04% 519
2017
Q2
$5.22M Sell
46,951
-6,156
-12% -$651K 0.06% 406
2017
Q1
$5.21M Sell
53,107
-8,293
-14% -$791K 0.06% 406
2016
Q4
$5.64M Buy
61,400
+3,436
+6% +$296K 0.07% 364
2016
Q3
$4.91M Buy
57,964
+2,336
+4% +$196K 0.06% 387
2016
Q2
$4.53M Sell
55,628
-2,404
-4% -$183K 0.06% 391
2016
Q1
$4.15M Buy
58,032
+10,111
+21% +$678K 0.06% 404
2015
Q4
$3.41M Buy
47,921
+20,629
+76% +$1.39M 0.06% 444
2015
Q3
$1.68M Sell
27,292
-14,138
-34% -$988K 0.03% 645
2015
Q2
$3M Sell
41,430
-3,685
-8% -$272K 0.05% 502
2015
Q1
$3.47M Buy
45,115
+21,750
+93% +$1.56M 0.06% 469
2014
Q4
$1.57M Buy
23,365
+1,913
+9% +$121K 0.03% 677
2014
Q3
$1.3M Buy
21,452
+2,648
+14% +$163K 0.03% 716
2014
Q2
$1.1M Buy
18,804
+3,005
+19% +$176K 0.02% 794
2014
Q1
$915K Buy
15,799
+11,138
+239% +$597K 0.01% 788
2013
Q4
$250K Sell
4,661
-734
-14% -$43.5K ﹤0.01% 1062
2013
Q3
$334K Buy
+5,395
New +$323K 0.01% 945

Other funds holding DGX

Natixis Advisors's DGX Position: Q2 2026 in Review

Natixis Advisors increased its Quest Diagnostics (DGX) stake by 3.4% in Q2 2026, buying an estimated $651K and bringing the position to 102,188 shares worth $21.7M. The position accounts for 0.02% of the portfolio, ranked #524.

Natixis Advisors first reported a position in DGX in Q3 2013 and has held it in 52 quarters since. The position peaked at $24.3M in Q3 2025. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Natixis Advisors held 102,188 shares of Quest Diagnostics worth $21.7M as of Q2 2026.
  • Natixis Advisors bought 3,315 Quest Diagnostics shares in Q2 2026, an estimated $651K.
  • Quest Diagnostics made up 0.02% of Natixis Advisors's portfolio in Q2 2026, its #524 holding.
  • Natixis Advisors first reported a position in Quest Diagnostics in Q3 2013 and has held it in 52 quarters since.
  • Natixis Advisors's Quest Diagnostics position peaked at $24.3M in Q3 2025.
  • 1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.